A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis

被引:23
|
作者
Meyers, Lindsay [1 ]
Groover, Chassidy J. [1 ]
Douglas, Joshua [1 ]
Lee, Sangmin [1 ,2 ]
Brand, David [1 ]
Levin, Michael C. [1 ,2 ]
Gardner, Lidia A. [1 ,2 ]
机构
[1] Res Serv VAMC, Memphis, TN 38104 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN 38163 USA
关键词
Multiple sclerosis; Apolipoprotein A-I; EAE; Neurological disease; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRANSCRIPTION FACTOR FOXP3; HIGH-DENSITY-LIPOPROTEIN; HIGH-DOSE SIMVASTATIN; REGULATORY T-CELLS; FLUORO-JADE-C; IL-23/IL-17; AXIS; TRANSGENIC MICE; MS-STAT; ATORVASTATIN;
D O I
10.1016/j.jneuroim.2014.10.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Apolipoprotein A1 (Apo A-I), the most abundant component of high-density lipoprotein (HDL), is an anti-inflammatory molecule, yet its potential role in the pathogenesis of multiple sclerosis (MS) has not been fully investigated. In this study, Western blot analyses of human plasma showed differential Apo A-I expression in healthy controls compared to MS patients. Further, primary progressive MS patients had less plasma Apo A-I than other forms of MS. Using experimental allergic encephalomyelitis (EAE) as a model for MS, Apo A-I deficient mice exhibited worse clinical disease and more neurodegeneration concurrent with increased levels of pro-inflammatory cytokines compared to wild-type animals. These data suggest that Apo A-I plays a role in the pathogenesis of EAE, a model for MS, creating the possibility for agents that increase Apo A-I levels as potential therapies for MS. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:176 / 185
页数:10
相关论文
共 50 条
  • [41] ASPECIFICITY OF APOLIPOPROTEIN A-I ANTISERA
    COBBAERT, C
    BERTELS, I
    STAELS, B
    VERHOEVEN, G
    LISSENS, W
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (05): : 291 - 291
  • [42] IMMUNOLOGICAL ESTIMATION OF APOLIPOPROTEIN A-I
    AYRAULTJARRIER, M
    BOBILEWICZ, D
    PASTIER, D
    BEUCLER, I
    POLONOVSKI, J
    ANNALES DE BIOLOGIE CLINIQUE, 1982, 40 (03) : 187 - 194
  • [43] Human Apolipoprotein A-I Deficiency
    Schaefer, Ernst J.
    Santos, Raul D.
    HIGH DENSITY LIPOPROTEINS, DYSLIPIDEMIA, AND CORONARY HEART DISEASE, 2010, : 55 - +
  • [44] The promise of apolipoprotein A-I mimetics
    Mendez, Armando J.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2010, 17 (02) : 171 - 176
  • [45] Elucidating the role of the putative ''apolipoprotein E-like'' domain of chicken apolipoprotein A-I
    Kiss, RS
    Francis, GA
    Ryan, RO
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 19 - 19
  • [46] Apolipoprotein A-I is a molecular lariat
    Segrest, JP
    Harvey, S
    Jones, MK
    CIRCULATION, 1998, 98 (17) : 2 - 2
  • [47] PHOSPHORYLATION OF HUMAN APOLIPOPROTEIN A-I
    BEG, ZH
    STONIK, JA
    HOEG, JM
    DEMOSKY, SJ
    BREWER, HB
    CIRCULATION, 1987, 76 (04) : 117 - 117
  • [48] Apolipoprotein A-I mimetic peptides
    Anantharamaiah, GM
    Navab, M
    Reddy, ST
    Hama, S
    Hough, G
    Palgunachari, MN
    Datta, G
    Garber, DW
    Fogelman, AM
    BIOPOLYMERS, 2005, 80 (04) : 498 - 498
  • [49] HUMAN APOLIPOPROTEIN A-I DEFICIENCY
    Schaefer, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [50] Features of interaction of complexes cortisol-apolipoprotein A-I and tetrahydrocortisol-apolipoprotein A-I with eukariotic DNA
    Panin, LE
    Tuzikov, FV
    Tuzikova, NA
    Polyakov, LM
    MOLECULAR BIOLOGY, 2006, 40 (02) : 300 - 309